GleamWall
中文EN

PCVX Vaxcyte, Inc.

Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1649094 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-74.8%
TTM EPS YoY-66.0%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-42.7%
ROA-37.3%
ROIC (approx.)-39.1%
Asset turnover—

Leverage & solvency

Liabilities / assets16.7%
Debt / equity0.00x
Current ratio4.56x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.84x
Accruals ratio-6.1%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue————————
R&D expense$270.33M$267.85M$312.78M$242.06M$209.93M$194.18M$148.13M$133.61M
SG&A expense$37.95M$34.92M$33.07M$32.22M$32.45M$32.04M$32.66M$28.55M
Operating income-$308.27M-$302.78M-$345.85M-$274.28M-$242.38M-$226.22M-$180.79M-$162.17M
Income tax$0$0$0$0$0$0$0$0
Net income-$297.06M-$284.30M-$320.62M-$246.51M-$212.83M-$166.57M-$140.72M-$137.08M
EBITDA-$302.47M-$299.77M-$342.90M-$266.79M-$239.28M-$223.34M-$177.84M-$159.31M
EPS (basic)-1.99-1.97-2.30—-1.56-1.22-1.04—
EPS (diluted)-1.99-1.97-2.30—-1.56-1.22-1.04—
Dividends declared per share0.00——0.000.00——0.00
Weighted avg. shares (diluted)148.91M144.49M139.51M—136.20M136.03M135.69M—
Balance sheet
Cash & equivalents$125.47M$183.19M$260.84M$173.96M$281.08M$306.74M$346.85M$389.19M
Short-term investments$1.17B$1.30B$1.48B$1.39B$1.43B$1.35B$1.32B$1.36B
Current assets$1.35B$1.55B$1.81B$1.63B$1.77B$1.72B$1.72B$1.79B
PP&E, net$253.36M$260.39M$260.69M$257.37M$253.49M$242.27M$217.16M$198.04M
Total assets$2.99B$3.14B$3.35B$3.00B$3.17B$3.31B$3.38B$3.51B
Current liabilities$295.70M$271.28M$242.08M$205.75M$200.05M$154.49M$97.00M$140.18M
Total liabilities$499.92M$380.21M$352.29M$317.21M$278.72M$234.03M$178.08M$205.50M
Shareholders' equity$2.49B$2.76B$3.00B$2.69B$2.89B$3.07B$3.20B$3.31B
Shares outstanding149.30M144.79M144.31M131.06M130.03M129.82M128.94M124.89M
Cash flow statement
Operating cash flow-$224.08M-$232.47M-$280.62M-$224.83M-$143.31M-$121.17M-$166.27M-$111.40M
Capital expenditure$3.33M$4.32M$2.11M$2.65M$3.82M$1.81M$5.42M$4.02M
Free cash flow-$227.42M-$236.79M-$282.73M-$227.49M-$147.13M-$122.98M-$171.70M-$115.42M
Investing cash flow$170.77M$147.72M-$233.41M$115.12M$121.17M$77.74M$123.32M-$557.17M
Financing cash flow-$5.33M$5.70M$601.58M$2.41M-$3.67M$2.52M$759,000$4.91M
Depreciation & amortization$5.80M$3.00M$2.95M$7.50M$3.10M$2.88M$2.96M$2.86M
Stock-based compensation$41.10M$41.24M$37.96M$36.00M$35.31M$36.93M$30.61M$24.37M

Free plan shows the latest 8 periods; Pro shows all 31 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.